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Summary
Preeclampsia (PE) is one of the most common dis-
eases worldwide, complicating ~5% of all pregnancies.
Although no major progress has been achieved in the
treatment of PE, our ability to identify women at high-
risk has increased considerably during the past de-
cade. 
The early identification of patients with an increased
risk for preeclampsia is therefore one of the most im-
portant goals in obstetrics. Today, several markers may
offer the potential to be used, most likely in a combi-
natory analysis, as predictors or diagnostic tools. We
present here the current knowledge on the biology of
preeclampsia and review several biochemical markers
which may be used to monitor preeclampsia in a fu-
ture, that, we hope, is not to distant from today.
Key words: preeclampsia; early diagnosis; hypertension; flt-
1; sEng; P-selectin; effDNA; ADAM12; PP-13; PTX3; PAPP-
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Introduction 
Preeclampsia occurs in 2–5% of pregnancies in the Occi-
dent, but it complicates up to 10% of pregnancies in the
developing countries, where emergency care is often
inadequate or lacking. Therefore we are in need of a
widely applicable and affordable test that could permit
presymptomatic diagnosis in order to identify and monitor
the patients at risk and thus provide the best prenatal
care for these women and their child. Such a test would
also be of benefit to confirm a confounding clinical diag-
nosis and for future studies investigating prophylactic
treatments or temporizing therapies.
To be effective a screening test need to be sufficiently
sensitive and specific and must provide an adequate pos-
itive predictive value. Today, several promising markers
have been described, alone or in combination, that might
fulfill these criteria. However, these data came often from
small case studies with selected populations. Therefore,
there is a need for worldwide large scale prospective
studies to confirm the sensitivity and specificity of these
promising markers and assess their utility in different sub-
types of preeclampsia before they could serve in clinically
useful screening tests.
Preeclampsia
Preeclampsia is a multi-system disorder of pregnancy,
which is characterized by new onset hypertension (sys-
tolic and diastolic blood pressure of ≥ 140 and 90 mm Hg,
respectively, on two occasions, at least 6 hours apart)
and proteinuria (protein excretion of ≥ 300 mg in a 24 h
urine collection, or a dipstick of ≥ 2+), that develop after
20 weeks of gestation in previously normotensive
women1, 2.
Dependent on the systemic involvement, several other
symptoms, such as edema, disturbance of haemostasis,
renal or liver failure, and the HELLP syndrome (hemoly-
sis, elevated liver enzymes, and low platelet counts) also
complicate the clinical picture. Preeclampsia can have an
early onset (preeclampsia starting before 34 weeks of
gestation) or late onset (preeclampsia starting after 34
weeks of gestation), can show mild or severe symptoms
(systolic blood pressure ≥ 160 mmHg or diastolic blood
pressure ≥ 110 mmHg, proteinuria >5 g/24 hours, olig-
uria, neurological symptoms, other clinical symptoms
such as deranged liver function, thrombocytopenia < 100
000 mm3, HELLP syndrome), and can evolve in eclamp-
sia in the most severe cases. In addition, it can manifest
as a maternal disorder only, with an appropriate fetal
growing, or it can present itself with a growth restricted
fetus (intrauterine growth restriction (IUGR)) or sudden
fetal distress.
Pathophysiology
The precise origin of preeclampsia remains elusive, but
it is believed to be likely multifactorial. A certainty is the
central role played by the placenta in its pathology 3, 4, 5, 6.
A long standing hypothesis has been that preeclampsia
develops as a consequence of some kind of immune
maladaptation between the mother and the fetus during
the very first weeks of pregnancy, leading to a 2-step dis-
order progression that can be summarized as following:
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in a first – asymptomatic – step, local aberrant feto-mater-
nal immune interactions within the uterine wall lead to
impaired tissue and arterial invasion by trophoblast cells.
This results in failed transformation of the uterine spiral
arteries and subsequently worsened placental perfusion.
Chronic hypoxia or alternate periods of hypoxia/re-oxy-
genation within the intervillous space is expected to
trigger tissue oxidative stress and increase placental
apoptosis and necrosis 7, 8 (Fig. 1).
The clinical disorder arises, in a second step, when the
maternal vascular and immune systems cannot handle
any longer the increased shedding of placental-produced
debris and the aberrant expression of pro-inflammatory,
anti-angiogenic and angiogenic factors, leading to a sys-
temic endothelial cell dysfunction and an exaggerated
inflammatory response 1, 9, 10. Recently, this hypothesis
has been challenged 11.
It was proposed instead that intrinsic failure in trophoblast
differentiation at different time points of ontogeny may
lead to either a mild disorder with late-onset appearance,
or IUGR complicated or not with the maternal symptoms.
However, the origin of preeclampsia might not be
restricted to an alteration of trophoblast differentiation, but
may also in some cases depend on an underlying mater-
nal constitutional factors such as genetic, obesity,
dysfunctional maternal clearance or inflammatory sys-
tems 12.
Material and Methods
Since many years, different biophysical and biochemical
markers have been investigated, based on pathophysio-
logical observations that have been noted in case of
preeclampsia, such as placental dysfunction, a general-
ized inflammatory response, endothelial dysfunction and
activation of the coagulation system.
Using a series of keywords, we reviewed electronic data-
bases (Medline, Elsevir ) reporting the performance of
biological markers to predict preeclampsia, both single
markers and combinations of markers.
Biomarkers
Angiogenic factors
Angiogenesis requires the complex interplay between the
pro-angiogenic factors vascular endothelial growth factor
(VEGF) and placental growth factor (PlGF) with their cog-
nate receptors VEGF receptor-1 (VEGFR-1, which is
alternatively called fms-like tyrosine kinase (flt)-1) and
VEGFR-2 (for a review on the function of these factors13).
Interestingly, the placenta is a rich source of these fac-
tors14, 15.
In addition to regulating blood vessel homeostasis, VEGF,
PlGF and the flt-1 receptor have been shown to be key
components in regulating trophoblast cell survival and
function 14, 16.
Placental cells also secrete a soluble isoform of flt-1,
which is generated through alternative splicing of the
messenger RNA and acts as an anti-angiogenic factor by
interacting with, and thereby neutralizing, PlGF and
VEGF17.
There is strong evidence for the occurrence of higher pla-
cental expression of sflt-1 and repeated findings of
elevated circulating levels of sflt-1 and reduced free
bioactive PlGF and VEGF in preeclamptic patients 9, 18, 19,
20, 21
. 
It was thus suggested that a part of this excess of circu-
latory sflt- 1 may stem from the placenta. Maternal blood
levels of sflt-1 were shown to correlate with the severity
of preeclampsia, whereas, in an opposite manner, the
quantities of bioactive VEGF and PlGF were further
decreased in patients with severe symptoms compared
to normal pregnant women or preeclamptic patients with
mild symptoms 9, 18, 22. Alterations in sflt-1 and PlGF are
also more pronounced in early onset in comparison to
late onset preeclampsia 22, 23.
However, it was also shown that increased levels of sflt-
1 were also associated with IUGR 24.
Remarkably, when introduced into pregnant rats, exoge-
nous sflt-1 triggers hypertension and proteinuria,
symptoms akin to those in preeclampsia 9.
According to some studies, the presymptomatic alter-
S. Monte
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ations in sflt-1 levels appeared to be specific for
preeclampsia as no changes are detected in women who
later deliver SGA neonate or whose pregnancies are
complicated by IUGR, compared to women with normal
pregnancy outcome 25, 26.
However, others found that in a selected group of patients
with abnormal uterine perfusion, similar alterations in sflt-
1 and PlGF levels could be detected during the second
trimester in cases with subsequent IUGR 27.
Nevertheless, owing to the evolving unbalance of angio-
genic factors after 25 weeks of gestation in women with
subsequent preeclampsia, the ratio sflt-1/PlGF has been
advocated to be a reliable marker of overall preeclamp-
sia risk. As a matter of fact, soluble flt-1 and PlGF have
been launched by Roche as a screening test for
preeclampsia in the second trimester in Europe and is
expected to be submitted to the FDA soon.
It has recently been reported that patients with
preeclampsia have lower plasma concentrations of solu-
ble VEGF-R2 28.
However, this biomarker may not be specific for
preeclampsia as an equivalent decrease was observed
in patients with SGA babies in the absence of preeclamp-
sia.
Soluble Endoglin
Endoglin (Eng) is a co-receptor for transforming growth
factor (TGF)- 1 and TGF- 3 that is highly expressed on
cellular membranes of the vascular endothelium and on
the syncytiotrophoblast 29, 30.
It functions as a modulator of TGF- signaling and is
involved in angiogenesis and the regulation of the vas-
cular tone 31, 32.
A circulatory form of endoglin, which consists of the extra
cellular part of the molecule that may be produced
through the proteocleavage of the placental membrane-
bound form, has been identified in normal pregnancy and
in preeclampsia.
In vitro, sEng acts as a negative regulator of angiogene-
sis by competitive interaction with TGF- , thereby
impairing capillary formation by endothelial cells. Fur-
thermore, it induces high arterial pressure and vascular
permeability in pregnant rats in which the protein was
over-expressed. Very interestingly, the combined intro-
duction of sEng and sflt-1 in the pregnant animals
induced renal, placental and hepatic changes reminis-
cent of the HELLP syndrome 33.
Soluble Eng is present in substantial excess in
preeclamptic patients compared to normotensive con-
trols, and its concentrations appear to increase with the
severity of the symptoms and are the highest in
preeclampsia complicated by the HELLP symptom24,33,34.
Pregnancies with IUGR without the maternal syndrome
may also be characterized by elevated levels of sEng,
suggesting that this factor is not specific for preeclamp-
sia, but may be a marker for clinical conditions associated
with an underlying placental pathology 24, 34.
However, these results remain conflicting as others
demonstrated no association between IUGR and the lev-
els of sEng. Moreover, a pilot study has suggested that
sEng may prove useful in differentiating preeclampsia
from other hypertensive diseases of pregnancy, such as
gestational or chronic hypertension 35.
Large scale studies will be needed in order to clarify
these important issues.
Like sflt-1, sEng concentrations raise during the last 2
months of normal pregnancy. In pregnancies ending with
preeclampsia, this increase occurs earlier and is steeper
26, 36, 37
.
The distinction becomes significant starting 9 - 11 weeks
before the clinical symptoms, for both early and late onset
preeclampsia, but is more prominent for preterm
preeclampsia or in women in whom preeclampsia is com-
plicated with SGA. Altered levels of this factor throughout
gestation are also associated with SGA pregnancies
without the maternal symptoms 26, 38.
Thus, a specific prediction cannot be achieved with this
analyses alone.
Several longitudinal case-control studies have therefore
evaluated the potential of sEng in combination with the
pro- and anti-angiogenic factors PlGF and sflt-1 for the
prediction of preeclampsia 26, 36.
The studies reported that the pattern of changes in the
ratio of different combinations of these factors
(PlGF/sEng; (sflt- 1+sEng)/PlGF; etc), collected at 13
weeks and around 20 weeks, was more informative than
the individual biomarkers at single time-point screening.
One study suggested that a rigorous monitoring of the
sequential changes in the profile of these three biomark-
ers between the first and the second trimesters permits
sensitive and specific risk assessment 38.
A change in PlGF/sEng ratio that was below the median
slope for controls conferred an odds ratio of 7.68 for the
development of pre-term preeclampsia, and 2.46 for the
development of term preeclampsia, and discriminated
SGA pregnancies from preeclampsia. Further studies
with large number of patients will be required to confirm
these very promising preliminary results and assess the
utility of analyzing these biomarkers in the clinical routine.
P-Selectin
P-selectin is a member of the selectin family of cell sur-
face adhesion molecules. It is expressed by platelets and
endothelial cells upon activation and plays crucial roles
in inflammatory reactions by supporting the recruitment
and activation of circulating leucocytes, and in coagula-
tion through the generation of leukocyte-derived
“bloodborne” tissue factor 39, 40.
P-selectin is rapidly shed from the cellular membrane of
activated platelets and this release is suggested to con-
tribute to most of the soluble isoform of the molecule that
is found in the plasma 41.
Preeclampsia is associated with extensive platelet acti-
vation 42.
P-selectin-exposing micro particles with procoagulant
activity, released from activated platelets, have been
detected in the peripheral blood of preeclamptic women
43, 44
. In addition, soluble P-selectin has been repeatedly,
though not constantly, observed in higher amounts in
serum or plasma of patients with this disorder 45, 46.
Interestingly, it has recently been shown that alterations
in the levels of soluble P-selectin before 20 weeks of ges-
tation antedate the symptoms47,48. This early
up-regulation of soluble P-selectin has been suggested
to reflect the early but still asymptomatic disturbances of
the maternal vascular system. In one of these studies, P-
selectin was identified as the marker with the highest
discriminatory ability among three biomolecules evalu-
ated between gestational weeks 11 to 15 47.
However, the combination of P-selectin with the two other
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markers, namely Activin A and VEGFR, showed a detec-
tion rate of only 59% (with a false-positive rate of 5%),
which is not sufficient for a possible routine clinical imple-
mentation as a screening test.
Cell-free fetal DNA
Since its detection in maternal plasma many approaches
have been tested to use cell free fetal DNA for non-inva-
sive diagnostic approaches. These include qualitative
analyses like fetal sex analysis 49, determination of the
fetal Rhesus status 50, 51or the analysis of fetal point muta-
tions 52 as well as the quantitative analysis as an indicator
for several fetal anomalies, e.g. fetal growth restriction 53,
polyhydramnios 54, trisomy 55 or preterm labor 56.
The value of cffDNA in maternal plasma as an indicator
for preeclampsia has first been reported by Lo et al. in a
small scale study in the plasma of 20 preeclamptic
women and 20 gestational age matched controls in the
third trimester, where cffDNA was increased approxi-
mately 5-fold in women with preeclampsia 57. The same
effect was observed in the second trimester in a study by
Zhong et al. in 10 preeclamptic women and 40 controls
58
. The so far biggest study in that field was conducted by
Levine et al. with 120 preeclamptic women and 120 con-
trols: A two- to five-fold increase of cffDNA levels was
monitored starting from week 17 until three weeks before
the onset of preeclampsia 59.
As the amount of fetal DNA is routinely determined by
quantifying Y-chromosome specific sequences, e.g. SRY
(sex determining region Y) and DYS 60, alternative
approaches have been tested to overcome this limitation:
An increase of total cell free DNA was observed in
women with preeclampsia at term 61, 62, 63 and before the
onset of preeclampsia 63. Furthermore, approaches to
analyze cffDNA independent from fetal sex, using epige-
netic differences between maternal and fetal DNA have
been developed, e.g. the use of the maspin gene, which
is hypomethylated in fetal tissue 64 or the hypermethy-
lated fetal promoter sequence of RASSF1A 65.
Although these approaches are promising, only one
study quantifying cffDNA with the RASFF1A approach in
10 women with preeclampsia and 20 controls has been
published 66. cffDNA has shown some predictive value for
the prediction of preeclampsia between 20–25 weeks of
gestation, however, higher sensitivities and specificities
can be obtained by combining several markers as has
been shown in a nested case-control study for cell free
DNA combined with Inhibin A in the second (n = 15 at
risk for PE), n = 68 controls) and third trimester (n = 34
preeclampsia, n = 44 controls) 67.
Currently, several multicenter studies are being per-
formed to confirm the predictive value of cffDNA to
predict and monitor preeclampsia in combination with
other potential markers, e.g. P-selectin, PAPP-A, PP-13,
sflt-1, sEng, PlGF).
ADAM12
ADAM12 (a disintegrin and metalloprotease 12) is a
membrane bound zinc dependant protease and belongs
to the ADAM protein family, a group of proteins involved
in cell-cell and cell-matrix interactions in fertilization, mus-
cle development and neurogenesis 68, 69. For this gene,
two alternatively spliced transcripts are known, a short
secreted form and a long membrane-bound form 70. The
plasma concentration of ADAM12 has been found to be
altered in several pregnancy related disorders. Several
studies have demonstrated that the plasma level of
ADAM12 is decreased in women carrying a fetus with tri-
somy 21 and trisomy 18 71, 72, 73. It has also been shown
that the ADAM12 concentration is decreased in women
with other aneuploidies and in women with low for gesta-
tional age birth weights 74.
The first connection of ADAM12 serum levels to
preeclampsia was demonstrated by Laigaard et al. in a
study with 160 women with preeclampsia and 324
healthy controls in the first trimester 75. The serum con-
centration of ADAM12 was significantly decreased in
women that later developed preeclampsia. These results
were confirmed by Spencer et al. in a study with two
groups (1. n = 64 PE, n = 240 controls, 2: n = 24 cases,
n = 144 controls) 76. However another study failed to con-
firm these promising results but concluded that
measurement of ADAM12 does not provide useful pre-
diction of SGA, preeclampsia, or spontaneous preterm
delivery 77.
PP-13
Placental protein 13 (PP-13, galectin-13) was first iso-
lated in 1983 by Bohn et al. 78, 79. It is a relatively small
protein with 139 amino acids (16,118 kDa) which is highly
homologous (69%) to the human eosinophil Charcot-Ley-
den Crystal protein, a phospholipase that belongs to the
beta-galactoside binding S-type animal lectin super fam-
ily. The homodimer which is linked by disulfide bonds
probably has special haemostatic and immunobiological
functions at the feto-maternal interface or a developmen-
tal role in the placenta 80. The 600 bp mRNA transcript is
only detectable in placental tissue but not in any other
fetal or adult tissue 78, 79, 81, 82.
The serum levels of PP-13 slowly increase during a nor-
mal pregnancy but abnormally low levels of PP-13 were
detected in first trimester serum samples of women sub-
sequently developing fetal growth restriction and
preeclampsia, in particular cases with early onset 83, 84.
Elevated serum concentrations of PP-13 have been
found in the second and third trimester in women with
preeclampsia, IUGR and in preterm delivery 85. For this
study 514 controls, 69 cases with preeclampsia, 69
cases with IUGR, 52 cases with preterm delivery and 24
cases with preeclampsia developing before 34 weeks of
gestation have been included.
Another study concluded that first-trimester serum levels
of PP-13 may serve as a suitable marker for preterm
preeclampsia but are weak for the prediction of severe
preeclampsia and ineffective for mild preeclampsia at
term 86. Here again the combination of several diagnos-
tic tools results in improved predictive power as was
shown by combined measuring of first trimester serum
PP-13 levels and median uterine artery pulsatility index
by ultrasound.This combination achieved a detection rate
for preeclampsia of 90% with a false positive rate of 6%
87
. However, this combination of serum PP-13 levels and
uterine artery pulsatility index loses its predictive power
when late second trimester (22–24 weeks of gestation)
serum is analyzed 88.
Currently a commercial PP-13 test kit is developed for the
first trimester screening for preeclamp sia by Diagnostic
Technologies, Haifa. The test has already been approved
in Europe and approval in the United States is expected
in the near future.
S. Monte
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PTX3
Pentraxin 3 (PTX3, tumor necrosis factor stimulated
gene- 14 89) belongs to the same family as C-reactive
protein (CRP) or serum amyloid P component (SAP) and
consists of 381 amino acids. The C-terminus is highly
homologous to SAP and CRP whereas the N-terminus
doesn’t show any homology to other proteins. The
according gene is organized into three exons 90 and is
extremely evolutionarily conserved from horseshoe crab
to human 91.
Responding to proinflammatory stimuli CRP, SAP and
PTX3 are produced by various tissues. It is also
expressed in tissues undergoing cell death. PTX3 then
interacts with several growth factors, extra cellular matrix
components and certain pathogens but is also involved
in the activation of the complement system 92 and facili-
tates pathogen recognition by phagocytes 93.
During pregnancy, PTX3 is increasingly expressed in
amniotic epithelium, chorionic mesoderm, trophoblast ter-
minal villi, and perivascular stroma of placentae 93. Cetin
et al. and Rovere-Querini et al. showed that in case of a
future preeclampsia and IUGR the PTX3 plasma levels
are even more increased in all three trimesters 94, 95.
So far no studies that combine PTX3 with other potential
markers have been performed. 
PAPP-A
PAPP-A (pregnancy-associated plasma protein A, pap-
palysin 1, insulin-like growth factor binding protein-4
protease, EC 3.4.24.79) is a disulfide bond linked homod-
imeric peptidase of 1628 amino acids and a mass of 400
kDa 96. It can be detected during pregnancy in maternal
circulation mainly as a complex with the proform of the
eosinophil major basic protein, an inhibitor of PAPP-A 97.
Although the reaction products are not identified yet,
insulin-like growth factor binding proteins are substrates
for the hydrolytic activity of PAPP-A 98. PAPP-A is sup-
posedly involved in local proliferative processes, for
example bone remodeling 99.
In the recent years decreased plasma levels of PAPP-A
have been reported in all trimesters in women with
preeclampsia 100, 101, 102, 103.
Discussion
Regardless of the lack of existing prophylactic and thera-
peutic means against preeclampsia, the search for
noninvasive, blood-borne or urinary biomarkers that
could predict the development or assist in the detection
of this life-threatening pregnancy disorder is still of utmost
importance. The availability of such markers could have
decisive impact on the medical management of pregnant
women and their child (e.g. refer to a tertiary centre) but
also on the health costs associated with this poor med-
ical condition.
So, early identification of pregnant women at risk for
preeclampsia is a priority to implement preventive meas-
ures.
Biochemical markers for prediction of preclampsia: review of the literature
Journal of Prenatal Medicine 2011; 5 (3): 6-7
Table I - Today the use of biomarkers in combination with uterine artery Doppler screening is promising as a potential screen-
ing tool.
0147 7 Biochemical_Monte:-  22-09-2011  16:27  Pagina 67
Conclusion
Despite there exists many different potential markers for
preeclampsia, the reliability of these markers in predicting
preeclampsia has been inconsistent between different
studies. Furthermore, preeclampsia is a multifaceted dis-
order, certain say it is not one but several diseases.
Therefore, there is a need for high quality, large scale
multicenter trials which enroll patients with different risks
of developing the syndrome and throughout multi-ethni-
cal background, in order to assess the predictive value of
different markers and finally propose the best marker
combination for a routine use in clinical settings.
Those biomarkers parameters have shown promising
predictive performance, but so far there is no clinically
validated screening procedure.
Below is a table about summary of potential biochemical
markers for the prediction (1° and 2° trimester) or the
detection (manifest preeclampsia) of preeclampsia in
maternal peripheral blood (Tab. 1).
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